Critical Contrast: IQVIA (IQV) & Its Competitors

IQVIA (NYSE:IQV – Get Free Report) is one of 109 publicly-traded companies in the “Life Sciences Tools & Services” industry, but how does it weigh in compared to its rivals? We will compare IQVIA to related businesses based on the strength of its earnings, profitability, valuation, analyst recommendations, dividends, institutional ownership and risk.

Volatility & Risk

IQVIA has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500. Comparatively, IQVIA’s rivals have a beta of 0.94, suggesting that their average stock price is 6% less volatile than the S&P 500.

Valuation and Earnings

This table compares IQVIA and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
IQVIA $17.31 billion $1.36 billion 29.85
IQVIA Competitors $2.26 billion $55.11 billion -7.35

IQVIA has higher revenue, but lower earnings than its rivals. IQVIA is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

89.6% of IQVIA shares are owned by institutional investors. Comparatively, 54.0% of shares of all “Life Sciences Tools & Services” companies are owned by institutional investors. 1.7% of IQVIA shares are owned by insiders. Comparatively, 14.8% of shares of all “Life Sciences Tools & Services” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for IQVIA and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IQVIA 1 2 16 2 2.90
IQVIA Competitors 960 3205 5536 179 2.50

IQVIA currently has a consensus target price of $294.21, suggesting a potential upside of 19.75%. As a group, “Life Sciences Tools & Services” companies have a potential upside of 4.76%. Given IQVIA’s stronger consensus rating and higher possible upside, equities analysts plainly believe IQVIA is more favorable than its rivals.

Profitability

This table compares IQVIA and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
IQVIA 8.05% 30.02% 6.52%
IQVIA Competitors -477.84% 79.93% -12.81%

Summary

IQVIA beats its rivals on 10 of the 13 factors compared.

About IQVIA

(Get Free Report)

IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company’s offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.